MedPath

A randomised study about the effect on survival of hormonal therapy versus hormonal therapy plus local external radiation therapy in patients with primary diagnosed metastasised (M+) prostate cancer.

Completed
Conditions
Prostate cancer
Registration Number
NL-OMON29395
Lead Sponsor
Onze Lieve Vrouwe Gasthuis, afdeling urologie, Amsterdam. Erasmus Medisch Centrum, afdeling urologie Rotterdam (P.C.M.S. Verhagen)
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
446
Inclusion Criteria

1. Histologically proven adenocarcinoma of the prostate;

2. Stage T1-4, G1-3, N0-2, M1;

Exclusion Criteria

1. Start therapy more than 8 weeks after the initial diagnoses;

2. Other treatment for prostate cancer before start of the studytherapy;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survival.
Secondary Outcome Measures
NameTimeMethod
1. Biochemical progression;<br /><br>2. Health related quality of life.
© Copyright 2025. All Rights Reserved by MedPath